Approved GLP-1 agonists include exenatide (Byetta, Bydureon), liraglutide (Victoza for diabetes, Saxenda for obesity), albiglutide (Tanzeum), dulaglutide (Trulicity), lixisenatide (Lyxumia in Europe, Adlyxin in the U.S.)and semaglutide (Ozempic, Rybelsus for diabetes, Wegovy for obesity). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.